Ligand Pharmaceuticals Inc expected to post earnings of 43cents a share - Earnings Preview

Ligand Pharmaceuticals Incorporated

04/11/2022 23:31

* Ligand Pharmaceuticals Inc  LGND.OQ   LGND.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 7. 
    * The San Diego California-based  company is expected to
report  a
41.0% decrease in revenue to $38.277 million from $64.84 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ligand
Pharmaceuticals
Inc is for earnings of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $140​, above​ its last closing price
of $62.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  0.46        0.43       1.03      Beat    139.5
 Mar. 31 2022  0.66        0.66       0.58      Missed  -11.7
 Dec. 31 2021  1.37        1.37       1.80      Beat    31.4​
 Sep. 30 2021  1.02        1.04       1.58      Beat    52.4
 ​​Jun.        1.34        1.36       1.63      Beat    19.7
 30 2021                                                
 Mar. 31 2021  1.14        1.13       1.41      Beat    25.3​
 Dec. 31 2020  1.00        0.99       1.62      Beat    63.6
 Sep. 30 2020  0.98        0.98       1.04      Beat    5.9
 This summary was machine generated November 4 at 23:31 GMT.  All
figures in US dollars  unless otherwise stated